Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 16Terminated 11Active not recruiting 5Unknown 4Recruiting 4Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Genitourinary 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Melanoma 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Small Cell Lung Cancer Recurrent 1Safety Issues 1Recurrent Liver Cancer After Liver Transplantation 1Recurrence 1Radiation Pneumonitis 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Locally Advanced or Metastatic Solid Tumors 1Liver Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 8Epirubicin 7Gemcitabine 6Cisplatin 6tislelizumab 5apatinib 5atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4toripalimab 3Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3Albumin-Bound Paclitaxel 3talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × atezolizumab × Clear all
NCT04739670 2024-03-01

BELLA

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
31 enrolled
Breast

Recurrence, Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Consorzio Oncotech

Phase 2 Unknown
49 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Infinity Pharmaceuticals, Inc.

Phase 2 Unknown
91 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡